Additionally, retrospective clinical analyses indicate that high TMEM16A expression in human prostate cancer specimens correlates with advanced TNM stages, Gleason scores, and lymph node metastasis [1, 4], thereby reinforcing its potential as a prognostic biomarker. Here, ANO1 is linked to prostate carcinoma.